Abstract
3017 Background: The addition of bevacizumab (rhu-anti-VEGF) to frontline chemotherapy for advanced colorectal cancer (CRC) improves survival. Bowel perforation and fistula formation have been reported in colorectal cancer patients treated with bevacizumab. Methods: ECOG conducted two trials of bevacizumab in patients with metastatic CRC: as frontline chemotherapy with IFL (E2200) and second line therapy with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) (E3200). Toxicity forms and severe adverse event reports were reviewed for bowel perforation and fistula formation. Results: In E2200, 86 patients were treated. There were 2 reports of bowel perforation and 2 reports of enterocutaneous fistulae. The bowel perforations occurred in cycles 1 and 10; both occurred at anastomotic sites. One perforation occurred 27 days after hemicolectomy. The fistulae occurred in cycles 1 and 6. In E3200, 824 patients were treated (290 chemotherapy alone, 292 chemotherapy with bevacizumab, and 242 bevacizumab alone). There ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
